HOME Top Market Reports BRIC Diabetes Drugs Market (2010-2015) in Brazil, Russia, India, China

BRIC Diabetes Drugs Market (2010-2015) in Brazil, Russia, India, China

By: marketsandmarkets.com
Publishing Date: April 2010
Report Code: PH 1207

Discount on Reports  

  Speak to Analyst Enquiry Before Buying Analyst Briefing  
purchase report
download pdf  request for customisation


Report Description

The prevalence of diabetes is on the rise across the globe due to increased life expectancy, changing lifestyles, and the rising incidence of obesity. Brazil’s diabetes drugs market is showing a double digit growth rate; while the Russian insulin market is also expected to witness significant growth with an estimated 20 million patients in the region requiring diabetes treatment by 2025.

India and China have the highest number of diabetics in the world – China alone is expected to have more than 71 million diabetic patients by 2025; and the similarly huge patient-base in India has already attracted a number of pharmaceutical companies such as Eli Lilly and Novo Nordisk. These companies are offering easy-to-use insulin versions to grab the market share in the Indian market for diabetes drugs. Thus, diabetes drugs market in BRIC economies is expected to have significant growth opportunities in the years to come.

Market Estimates and Forecasts

The report categorizes the BRIC Diabetes Drugs market as follows:

  • Injectables Market: (Insulin, exenatide)
  • Oral Drugs Market: (Metformin, Sulfonylureas, thaizolidinediones, dipeptidyl inhibitors, meglitinides, alpha glucosidase inhibitors, combination medications)

In addition to market tables for each submarket, each section of the report will provide market trends, drivers, and opportunities. The report also draws a competitive landscape, profiling the key players and the top-selling products in the diabetes drug market in BRIC.

What makes our reports unique?

  • We provide the longest market segmentation chain in this industry- not many reports provide market breakdown upto level 5.
  • We provide 10% customization. Normally it is seen that clients do not find specific market intelligence that they are looking for. Our customization will ensure that you necessarily get the market intelligence you are looking for and we get a loyal customer.
  • We conduct detailed market positioning, product positioning and competitive positioning. Entry strategies, gaps and opportunities are identified for all the stakeholders.
  • Comprehensive market analysis for the following sectors:
  • Pharmaceuticals, Medical Devices, Biotechnology, Semiconductor and Electronics, Energy and Power Supplies, Food and Beverages, Chemicals, Advanced Materials, Industrial Automation, and Telecom and IT. We also analyze retailers and super-retailers, technology providers, and research and development (R&D) companies.

Key questions answered

  • Which are the high-growth segments/cash cows and how is the market segmented in terms of oral drugs, injectables?
  • What are market estimates and forecasts; which markets are doing well and which are not?
  • Where are the gaps and opportunities; what is driving the market?
  • Which are the key playing fields? Which are the winning edge imperatives?
  • How is the competitive outlook; who are the main players in each of the segments; what are the key selling products; what are their strategic directives, operational strengths and product pipelines? Who is doing what?

Powerful Research and analysis

The analysts working with MarketsandMarkets come from renowned publishers and market research firms, globally, adding their expertise and domain understanding. We get the facts from over 22,000 news and information sources, a huge database of key industry participants and draw on our relationships with more than 900 market research companies across the world. We, at MarketsandMarkets, are inspired to help our clients grow by providing qualitative business insights with our huge market intelligence repository.

TABLE OF CONTENTS
Executive summary
Market overview
Market analysis
Antidiabetes drugs market
Competitive landscape
 
1 INTRODUCTION
  1.1 Key take-aways
  1.2 Report description
  1.3 Market estimates and forecasts
  1.4 Stakeholders
  1.5 Research methodology

2 SUMMARY

3 MARKET OVERVIEW
  3.1 Drivers
      3.1.1 Rising number of diabetics in bric
      3.1.2 Uptake of novel drugs drive sales
      3.1.3 Bric government initiatives
      3.1.4 Complexity of alternative diabetes management therapies
  3.2 Restraints
      3.2.1 Low patient awareness
      3.2.2 Cost sensitivity
  3.3 Opportunities
      3.3.1 Diabetes vaccines & inhalable insulin
      3.3.2 Increasing diabetes care centers
  3.4 Competitive analysis, by region
  3.5 Competitive analysis, by segment
  3.6 Competitive analysis, by products
  3.7 Age group analysis
  3.8 Key findings

4 MARKET ANALYSIS
  4.1 Brazil diabetes drugs market
      4.1.1 Drivers & restraints
           4.1.1.1 Initiatives by the brazilian government
     4.1.1.2 Patent expiry of key branded drugs
     4.1.1.3 Counterfeiting of drugs
      4.1.2 Brazilian government supportive of local players
      4.1.3 Distribution network in Brazil
      4.1.4 Reimbursement scenario
      4.1.5 Regulatory environment
  4.2 Russia diabetes drugs market
      4.2.1 Drivers & restraints
     4.2.1.1 Educational programs for self care
     4.2.1.2 Paucity of healthcare personnel
      4.2.2 Distribution network
      4.2.3 Regulatory environment
  4.3 India diabetes market
      4.3.1 Drivers & opportunities
        4.3.1.1 Highest number of diabetics in the world
     4.3.1.2 New budget earmarks more funds for diabetes control
      4.3.2 Restraints
     4.3.2.1 Cost issues
     4.3.2.2 Low level of patient awareness
      4.3.3 Regulatory environment
  4.4 China diabetes drugs market
      4.4.1 Competitive landscape
      4.4.2 Diabetes prevalence in provinces
      4.4.3 Distribution network
      4.4.4 Drivers & restraints
     4.4.4.1 Chinese government’s policy initiatives
     4.4.4.2 Limited infrastructure for diabetes care
      4.4.5 Reimbursement scenario
      4.4.6 Regulatory environment

5 ANTI-DIABETES DRUGS MARKET
  5.1 Injectables
      5.1.1 Insulin
      5.1.2 Drivers, restraints & opportunities
     5.1.2.1 Shift from oral antidiabetic drugs to insulin
     5.1.2.2 Cost issues
     5.1.2.3 Development of novel insulin delivery methods
      5.1.3 Incretin mimetics
      5.1.4 Exenatide versus insulin
  5.2 Oral antidiabetic drugs
      5.2.1 Drivers & restraints
     5.2.1.1 Novel drugs drive market growth
     5.2.1.2 Side effects & no long term control
     5.2.1.3 Patent expiries of blockbuster drugs
      5.2.2 Opportunities
      5.2.3 Metformin
      5.2.4 Sulfonylureas
      5.2.5 Sulfonylurea vs Metformin
      5.2.6 Thiazolidinediones
      5.2.7 Meglitinides
      5.2.8 Alpha glucosidase inhibitors
      5.2.9 Dipeptidyl peptidase inhibitors
      5.2.10 Combination medications

6 COMPETITIVE LANDSCAPE
  6.1 Bric oad market share
  6.2 Bric insulin market share
  6.3 Evolution of anti-diabetic drugs
 
7 COMPANY PROFILES
  7.1 ABBOTT LABORATORIES
  7.2 AUROBINDO PHARMA LTD
  7.3 BAYER HEALTHCARE AG
  7.4 BIOCON LTD
  7.5 BOEHRINGER INGELHEIM
  7.6 BRISTOL-MYERS SQUIBB
  7.7 DR. REDDY'S LABORATORIES LTD
  7.8 ELI LILLY AND COMPANY
  7.9 GLENMARK PHARMACEUTICALS LTD
  7.10 GLAXOSMITHKLINE PLC
  7.11 LUPIN LTD
  7.12 MERCK & CO. INC.
  7.13 NOVO NORDISK A/S
  7.14 PIRAMAL HEALTHCARE LTD
  7.15 RANBAXY LABORATORIES LTD
  7.16 ROCHE HOLDING LTD
  7.17 SANOFI-AVENTIS
  7.18 SHREYA LIFE SCIENCES PVT LTD
  7.19 SUN PHARMA INDUSTRIES LTD
  7.20 TAKEDA PHARMACEUTICALS COMPANY
  7.21 ZYDUS CADILA HEALTHCARE LTD

LIST OF TABLES 
 
Summary Table Bric Diabetes Drugs Market, By Products 2007 – 2014 ($Millions) 
1 Brazilian diabetes drugs market, by products 2007 – 2014 ($Millions)
2 Russian diabetes drugs market, by products  2007 – 2014 ($Millions)
3 Indian diabetes drugs market, by products  2007 – 2014 ($Millions)
4 Chinese diabetes drugs market, by products  2007 – 2014 ($Millions)
5 Bric injectables market, by products 2007 – 2014 ($Millions)
6 Bric injectables market, by geography 2007 – 2014 ($Millions)
7 Bric insulin market, by geography 2007 – 2014 ($Millions)
8 Bric incretin mimetics market by geography 2007 – 2014 ($Millions)
9 Bric oral antidiabetic drugs market, by products 2007 – 2014 ($Millions)
10 Bric oral antidiabetic drugs market, by geography 2007 – 2014($Millions)
11 Bric metformin market, by geography 2007 – 2014 ($Millions)
12 Bric sulfonylurea market, by geography 2007 – 2014 ($Millions)
13 Bric thiazolidinediones market, by geography 2007 – 2014 ($Millions)
14 Bric meglitinides market, by geography 2007 – 2014 ($Millions)
15 Bric alpha glucosidase inhibitors market, by geography 2007 – 2014 ($Millions)
16 Bric dipeptidyl peptidase inhibitors market, by geography 2007 – 2014 ($Millions)
17 Bric combination medications market, by geography 2007 – 2014 ($Millions)
18 Competitive developments in bric (2007-January 2010)
 
LIST OF FIGURES 
 
1 Prevalence of diabetes in bric (2009)
2 Rising diabetic population in bric (2000 – 2012)
3 India & China attract market players
4 Comparative analysis of the market aspects of bric
5 Market share of diabetes drugs (2009)
6 Shift of market from oral anti-diabetic drugs to insulin from 2009 to 2014
7 Dipeptidyl peptidase inhibitors - emerging class of drugs (2009)
8 Gap analysis of anti-diabetic drugs
9 Estimated prevalence of diabetes in age groups
10 Levels of diabetes therapy
11 Market share of anti-diabetic drugs in bric WRT prescription (%)
12 Evolution of sulfonylurea
13 Approximate share of antidiabetic drugs WRT revenues (%)
14 Company strategic focus
15 Profitable collaboration with glucose monitoring equipment manufacturers
16 Key market players in competitive development
17 Oral antidiabetic drugs market share analysis
18 Insulin market share analysis
19 Evolution of antidiabetes drugs

BRIC Diabetes Drugs Market

BRIC countries hold a significant share of the global market for diabetes drugs as they together account for 37% of the global prevalence of this disease condition. Driven by improvements in living standards, the rising incidence of diabetes in BRIC is expected to amount to a staggering 150 million patients by 2030, or about 40% of the world’s diabetic population.

The slowdown of the pharma market growth in developed economies has concentrated investor interest on BRIC nations, where the diabetes drug market has benefitted significantly from government initiatives for spreading patient awareness, and the subsequent increase in the uptake of novel drugs such as incretin mimetics (Eli Lilly’s Byetta) and dipeptidyl inhibitors (Merck’s Januvia and Novartis’ Galvus).

The BRIC diabetes drugs market is expected to grow from $3.9 billion in 2009 to reach $8.7 billion by 2014, growing at a CAGR of 17.1% from 2009 to 2014. Oral drugs accounted for around 65% of the market in 2009, but injectables are expected to have a higher CAGR of 21.9%.

Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Please visit http://www.marketsandmarkets.com/knowledge-process-outsourcing-services.asp to specify your custom Research Requirement

Connect With Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441
UK : 44-800-368-9399

Search reports



Access reports on all high
growth Drug Development Markets on KnowledgeStore
Request Demo